MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

Core Insights - MediciNova, Inc. announced an update on the ongoing Phase 2/3 clinical trial of MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis (ALS) at the 2024 Annual NEALS Meeting [1] - The trial's Principal Investigator, Dr. Björn Oskarsson, presented details on study design, objectives, and enrollment updates as of October 18, 2024 [1] - MN-166 (ibudilast) is a small molecule compound targeting neurodegenerative diseases and is in late-stage development for ALS, progressive MS, and DCM [2][3] Company Overview - MediciNova is a clinical-stage biopharmaceutical company with a focus on developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases [3] - The company has 11 programs in clinical development, with MN-166 (ibudilast) being the lead asset currently in Phase 3 trials for ALS and DCM [3] - MN-001 (tipelukast), another compound in development, is undergoing Phase 2 trials for idiopathic pulmonary fibrosis and non-alcoholic fatty liver disease [3]